- VIVUS, Inc. Board of Directors Expresses No Opinion and Remains Neutral Toward Icahn Group's Unsolicited Offer to Purchase 4.50% Convertible Senior Notes
- VIVUS Reports Second Quarter 2015 Financial Results
- VIVUS Announces Date of Second Quarter 2015 Update and Financial Results Conference Call
- VIVUS Announces Scientific Presentations
- VIVUS Reports First Quarter 2015 Financial Results
Latest EventsThere are currently no upcoming events
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.